LTR Pharma Signs Binding US Telehealth Term Sheet For ROXUS

LTR Pharma (ASX:LTP) said it has signed its first US commercial agreement for ROXUS, entering a binding telehealth commercialisation term sheet with Shed Holdings LLC.

The announcement gives the company a defined direct-to-consumer route to market through the Mavrox platform, however the arrangement still depends on Definitive Agreements being signed within 60 days and on launch-readiness work being completed.

The development matters because it shifts ROXUS from being part of a stated US strategy to an executed commercial framework.

In earlier company materials, LTR had outlined a dual US approach, with SPONTAN advancing through the FDA 505(b)(2) pathway and ROXUS intended to create earlier market presence through the personalised medicine route.

Today’s filing is the first time LTR has disclosed a binding commercial structure for that ROXUS pathway.

Under the term sheet, Shed Holdings is responsible for patient acquisition, telehealth and commercial infrastructure through Mavrox, while LTR Pharma remains the product owner, intellectual property holder and supplier.

How ROXUS Fits in

Before getting to the deal mechanics, it is worth clarifying what ROXUS is within LTR’s broader program.

The company’s erectile dysfunction portfolio is built around intranasal vardenafil, with SPONTAN as the FDA development pathway product and ROXUS as the brand tied to the earlier U.S. personalised medicine route.

In its April 2026 investor presentation, LTR said the two-track strategy was designed to pair the longer regulatory route for SPONTAN with a potentially earlier US commercial presence for ROXUS.

That earlier route is based on the Section 503A personalised medicine pathway, which the company said would involve supply through its designated US 503A pharmacy partner.

In practical terms, that means the telehealth agreement announced today is only one part of the setup.

The front-end patient channel is intended to come from Mavrox, but product fulfilment still depends on pharmacy onboarding and supply operations.

The company has previously pointed to some early market validation in Australia for the broader intranasal erectile dysfunction program.

Its April presentation said prescriptions under the TGA Special Access Scheme had passed 1,000, while the same presentation also outlined partnerships with Aptar Pharma for co-development and manufacturing platform work, Mayne Pharma for commercial manufacturing, and EBOS/Symbion for national distribution.

Those existing arrangements relate to the broader program rather than this US telehealth term sheet specifically, but they provide context for how LTR has been trying to build out commercial and supply capability through partners rather than internally.

Terms and Targets

The headline commercial number in the filing is a minimum commercial volume target of 150,000 ROXUS prescription units in the first 12 months from Commercial Launch.

LTR said that target is subject to supply and to the execution of Definitive Agreements.

That wording is important. The volume number gives investors a clearer commercial benchmark than a general strategy update, but it is not framed as an assured sales outcome.

The term sheet also grants two-year exclusivity in the U.S. direct-to-consumer telehealth channel from Commercial Launch.

However, that exclusivity is conditional on ongoing performance requirements, including the minimum-volume provisions.

If those requirements are not met, the filing states LTR Pharma may convert the arrangement to non-exclusive.

The initial term is two years from Commercial Launch, with annual auto-renewal unless either party elects not to renew.

The parties have 60 days from the effective date to negotiate and execute Definitive Agreements.

If that does not happen, the term sheet terminates and exclusivity ends automatically, apart from any surviving binding provisions.

The filing did not disclose revenue-sharing terms, launch expenditure, technology transfer costs or a precise first-sales date.

What Needs to Happen

The first point to watch is straightforward: whether LTR Pharma and Shed Holdings LLC convert the binding term sheet into Definitive Agreements within the 60-day window. If they do not, the current framework falls away.

The second issue is launch readiness. The company said supply will occur via its designated US 503A pharmacy partner, but today’s filing shows that fulfilment onboarding is still part of the required work.

The 150,000-unit first-year target is explicitly subject to supply, so pharmacy execution and manufacturing coordination are central.

The broader clinical and regulatory backdrop also remains relevant. LTR’s wider US strategy still includes SPONTAN through the FDA 505(b)(2) route.

In April 2026, the company reported interim Phase II pharmacokinetic and safety data showing a median Tmax of 10 minutes for SPONTAN 5 mg versus 60 minutes for oral vardenafil in an interim dataset of 27 subjects.

But the company also said final statistical analysis is expected in Q3 CY2026, and prior filings noted that FDA acceptance still depends on the final dataset and regulatory feedback.

Funding and spend remain part of the picture as well. LTR’s investor presentation in April cited $24.1 million in cash and zero debt, with quarterly operating cash outflow of $1.8 million.

Its half-year report showed cash of $25.8 million at 31 December 2025 and a loss before tax of $5.76 million for the period.

That suggests the company has funding for near-term milestones, but the existing filings also show rising losses and the need to keep execution on timetable.

Conditional US Route Opens

LTR has taken a tangible first step toward US commercialisation of ROXUS by securing a binding telehealth term sheet with Shed Holdings and defining a target volume and exclusivity structure.

But the agreement is still conditional on Definitive Agreements, launch readiness and supply execution, so the next two months and subsequent rollout steps are likely to determine how much of today’s announcement translates into actual market access.